A genome-wide high-throughput RNA interference screening performed in vitro in human cells has identified several genes that encode proteins capable of modulating levels of SMN, and, hence, are potential modifiers of SMA severity. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.